trending Market Intelligence /marketintelligence/en/news-insights/trending/1TeuG-GgDmk2iulB0lZlnw2 content esgSubNav
In This List

Akorn names CEO

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Akorn names CEO

Akorn Inc. appointed Douglas Boothe as the company's president and CEO, effective Jan. 1, 2019.

Boothe most recently served as president of Impax Laboratories Inc.'s generics division, since Aug. 1, 2016. In addition, he acted as executive vice president and general manager of prescription pharmaceuticals at Perrigo Co. PLC. He was also CEO, COO and executive vice president of Actavis LLC.

Lake Forest, Ill.-based Akorn is a specialty generic pharmaceutical company that develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter consumer health products, and animal health pharmaceuticals.